Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 03, 2015 5:50 AM ET

Biotechnology

Company Overview of Chronix Biomedical, Inc.

Company Overview

Chronix Biomedical, Inc., a molecular diagnostic company, develops DNA-based blood tests primarily for monitoring minimal residual disease (MRD) in cancer patients. It offers a breast cancer neoadjuvant companion diagnostic test that enables physicians to determine whether cancer remains in the body post chemotherapy; and develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood, and central nervous system. The company was founded in 1997 and is based in San Jose, California. It has laboratories in Göttingen, Germany; and Brookings, South Dakota.

5941 Optical Court

Suite 203E

San Jose, CA 95138

United States

Founded in 1997

Phone:

408-960-2306

Fax:

408-960-2305

Key Executives for Chronix Biomedical, Inc.

Co-Founder, Chief Executive Officer, Chief Science Officer and Director
Age: 61
Co-Founder and Director
Age: 63
Chief Financial Officer and Senior Vice President of Finance & Administration
Age: 57
Chief Oncology Expert and Member of Medical Advisory Board
Chief Technology Officer
Compensation as of Fiscal Year 2015.

Chronix Biomedical, Inc. Key Developments

Chronix Biomedical Appoints Nick Plowman as Chief Oncology Expert and Member of Medical Advisory Board

Chronix Biomedical announced that P. Nicholas Plowman MD, FRCR, FRCP has accepted the position of Chief Oncology Expert for Chronix Biomedical and will join the company’s Medical Advisory Board. Since 2000 he has been the Head of Clinical Oncology at Bartholomew’s Hospital and the Royal London Hospital. He sits on the Hospital Councils of the Bartholomew’s Hospital and is also Senior Oncologist to the Hospital for Sick Children, Great Ormond Street. At Chronix, Dr. Plowman will be advising on three plasma tests that the company has developed: Second Opinion(TM) test to help doctors decide whether to send men with elevated PSAs or women with suspicious M3 or M4 screening mammograms for a biopsy based on a Chronix blood test; Delta Dot Plots: the most accurate way to give oncologists timely feedback on whether conventional or targeted therapies are working; and Double Check(TM) Cancer Panels: the most accurate way to select actionable mutations with a blood test " and monitor changes in mutations during therapy.

Similar Private Companies By Industry

Company Name Region
Navitor Pharmaceuticals, Inc. United States
Transcriptic, Inc United States
Receptor BioLogix, Inc. United States
Research And Diagnostic Systems, Inc. United States
Shire Biologics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Chronix Biomedical, Inc., please visit www.chronixbiomedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.